Merck Tells Of 'Tortured Path' In Making Asthma Drug
CNNMoney.com
By Peter Loftus and Thomas Gryta TRENTON, NJ -(Dow Jones)- Merck & Co. (MRK) took a "tortured path" in developing its blockbuster asthma and allergy drug Singulair, a lawyer for the company told a judge Monday in an effort to ward off early generic …
Merck seeks to block Teva in US court Jerusalem Post
all 5 news articles